BMY - Goldman sees 17% upside in J&J in premarket analyst action May, 28 2019 08:54 AM Bristol-Myers Squibb Company AbbVie (NYSE:ABBV) resumed with Neutral rating and $84 (5% upside) price target at Goldman Sachs.More news on: AbbVie Inc., Allergan plc, Alder BioPharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...